Literature DB >> 30946234

Predicting Survival of Small Intestine Neuroendocrine Tumors: Experience From a Major Referral Center.

Susheian Kelly, Jeffrey Aalberg1, Alexandra Agathis, Katherine Phillips, Sara Haile, Kenneth Haines2, Michelle Kang Kim3, Celia M Divino1.   

Abstract

OBJECTIVE: Neuroendocrine tumors (NETs) comprise 41.8% of small intestine malignancies. The NET nomogram is a 15-item prognostic tool that includes relevant factors for guiding management decisions. This is the first external validation of this tool among American patients at a tertiary treatment center.
METHODS: Patients who underwent surgical intervention from 2005 to 2017 were screened by retrospective chart review. Nomogram scores were calculated following the methods outlined by Modlin et al (Neuroendocrinology. 2010;92:143-157). Validation assessed the association between nomogram scores and survival using Wilcoxon test and Cox regression.
RESULTS: Among the 121 patients selected, the NET nomogram significantly predicted survival as a continuous variable (P < 0.01) and when dichotomized using 83 points to distinguish low-risk versus high-risk groups (P < 0.01). However, the nomogram was not universally applicable as even at our specialty center, variables such as chromogranin A and urinary 5-hydroxyindoleacetic acid are not routinely collected, whereas others, like tumor grade, do not reflect the most recently updated classifications.
CONCLUSION: The NET nomogram accurately identified patients at low and high risk of death. However, revision to update prognosticators could improve its usefulness for predicting survival of small intestine NETs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30946234     DOI: 10.1097/MPA.0000000000001296

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

1.  Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors.

Authors:  Niko Hiltunen; Jukka Rintala; Juha P Väyrynen; Jan Böhm; Tuomo J Karttunen; Heikki Huhta; Olli Helminen
Journal:  Cancers (Basel)       Date:  2022-05-22       Impact factor: 6.575

2.  Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors.

Authors:  Praveen D Chatani; John G Aversa; James D McDonald; Tahsin M Khan; Xavier M Keutgen; Naris Nilubol
Journal:  Surgery       Date:  2021-04-02       Impact factor: 4.348

3.  Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Si Xie; Lei Li; Xiaotong Wang; Lequn Li
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

4.  A tool to predict survival in stage IV entero-pancreatic NEN.

Authors:  M Tarquini; M R Ambrosio; M Albertelli; P B de Souza; R Gafà; I Gagliardi; A Carnevale; P Franceschetti; M C Zatelli
Journal:  J Endocrinol Invest       Date:  2020-09-06       Impact factor: 4.256

Review 5.  Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art.

Authors:  Jhean Gabriel Gonzáles-Yovera; Pela J Roseboom; Marcio Concepción-Zavaleta; Isamar Gutiérrez-Córdova; Esteban Plasencia-Dueñas; María Quispe-Flores; Anthony Ramos-Yataco; Carlos Alcalde-Loyola; Frederick Massucco-Revoredo; José Paz-Ibarra; Luis Concepción-Urteaga
Journal:  World J Methodol       Date:  2022-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.